Trial Profile
A Two Arm Phase II Study of FOLFIRI in Combination With Standard or Escalating Dose of Cetuximab as First Line Treatment of K-Ras Wild Type Metastatic Colorectal Cancer: Everest 2.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms Everest2
- 10 Oct 2019 Status changed from active, no longer recruiting to completed.
- 02 Oct 2016 This trial was discontinued in Spain.
- 27 Aug 2016 This trial was discontinued in Austria.